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We report two pediatric female patients with systemic lupus erythematosus (SLE) who presented with decreased
vision. Both patients were found to have retinal vasculitis and occlusive disease. The first patient also presented
with vitreous hemorrhage and later non-arteritic ischemic optic neuropathy. She was treated with panretinal
photocoagulation and steroid therapy and later in her disease course was treated with rituximab and
cyclophosphamide. Her vision remained decreased. The second patient was treated with rituximab and monthly
cyclophosphamide infusions early in her disease course, and her vision improved dramatically. The difference in the
presentations and outcomes of these two pediatric patients with SLE highlights the spectrum of severity of SLE
retinopathy. We suggest that early recognition of disease and early intervention with B-cell depletion therapy in
addition to a traditional cytotoxic agent should be considered in pediatric patients with SLE and occlusive
retinopathy.
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Systemic lupus erythematosus (SLE) is a relatively rare
auto-immune disorder that may affect multiple organ
systems, including the eye. The most common ophthal-
mic manifestation of SLE is keratoconjunctivitis sicca
(dry eye syndrome). The most common intraocular
manifestation is retinopathy with microangiopathy due
to arterial occlusion [1,2], but other ophthalmic manifes-
tations may occur as well (e.g., uveitis, scleritis,
episcleritis, choroidopathy). The incidence of SLE-
associated retinopathy has been reported to be 7-29%
among adult patients [2,3], while occlusive retinopathy
has been found in approximately 3-11% of SLE patients
[3,4]. Retinopathy appears to be less common among
children with SLE, although to our knowledge, no inci-
dence studies have been published.
Retinal vasculitis can involve both the arteries and the
veins; however, the arteries are more frequently affected
in SLE [5]. Ophthalmic examination findings of retinal
vasculitis include the presence of vitreous cells and
sheathing of the retinal blood vessels. Occlusive retinal* Correspondence: tbeukelman@peds.uab.edu
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distribution, and reproduction in any mediumvasculitis may manifest with cotton wool spots
(representing nerve fiber layer infarcts), intraretinal
hemorrhages, optic nerve head swelling, and macular
edema [5-7]. Other findings, which may present later in
the course of the disease, include microaneurysms,
neovascularization related to ischemia, and tractional
retinal detachment. Fluorescein angiography–in which
sodium fluorescein dye is injected intravenously and ret-
inal photographs are taken as the fluorescein circulates
through the retinal vessels– highlights the leakage pro-
duced by damage to vessel walls (which form the inner
blood-retinal barrier) [5]. Optical coherence tomography
is a noninvasive diagnostic imaging modality used for
characterizing macular edema.
SLE retinopathy has been correlated with active lupus,
antiphospholipid antibody syndrome (APS), and central
nervous system lupus [7]; thus, its recognition is import-
ant for assessment of morbidity and prognosis. There
are few published reports of SLE-associated retinopathy
in the pediatric population. In this report we present
and discuss two pediatric patients with SLE who devel-
oped retinal vasculitis.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Patient #1
A 16-year-old African American female was diagnosed
with SLE in August 2010, after initially presenting to the
pediatric rheumatology clinic with abdominal pain, nau-
sea, vomiting, headache, fever, weight loss, and rash. She
was found to be ANA positive, with positive antibodies
to SS-A, SS-B, RNP, and dsDNA. Anti-cardiolipin anti-
body, anti-β2 glycoprotein 1 antibody, and lupus anti-
coagulant studies were negative. At that time she was
treated with hydroxychloroquine and a tapering dose of
oral prednisone.
She had no vision complaints until June 2011, when
she developed acute vision loss in the left eye. Her vision
in the right eye was 20/20 and count fingers at 2 feet in
the left eye. She was referred to a retina specialist, who
determined that she had a branch retinal artery occlu-
sion with macular ischemia, retinal neovascularization,
vitreous hemorrhage, and tractional retinal detachment
in the left eye. The patient also had evidence of non-
arteritic ischemic optic neuropathy (NAION). Later that
month, the patient’s vision was improved to 20/400 in
the left eye, and she underwent fluorescein angiography
to identify areas of retinal ischemia (see Figures 1 and 2).
She also received panretinal photocoagulation in the
left eye.
In August 2011, the patient complained of a “black
spot” in the superior medial region of her left eye. SheFigure 1 Fluorescein angiography of Patient #1 showing
normal fundus of right eye.began mycophenolate mofetil (MMF) for lupus retinopathy,
which was increased to 1,000 mg twice daily, together
with oral prednisone 20 mg daily. She underwent a
contrast-enhanced MRI of the brain, which showed no
evidence of vasculitis or other pathologic process.
By October 2011, she maintained stable vision of 20/
20 in the right eye and 20/400 in the left eye. Vitreous
hemorrhage in the left eye persisted and her optic nerve
now showed 1+ pallor. The retinal neovascularization
had regressed. Later that month, her MMF dose was in-
creased to 1,500 mg twice daily.
In April 2012, the patient returned to the retina spe-
cialist with an improvement in vision to 20/200 + 1 in
the left eye. Her dilated fundus examination remained
unchanged. She was found to have an afferent papillary
defect in the left eye as a result of the non-arteritic optic
neuropathy.
In June 2012, with the hope of gaining better control
of her SLE and preventing further vision loss, the patient
was treated with two rituximab infusions (750 mg/m2)
given 2 weeks apart and initiated monthly cyclophospha-
mide infusions (750 mg/m2 per dose) with concurrent
pulse methylprednisolone infusions (1,000 mg). At that
time MMF was discontinued while hydroxychloroquine
and prednisone were continued. She achieved successful
B-cell depletion following the rituximab infusions. In
November 2012 she returned to ophthalmology. Her vi-
sion remained 20/20 in the right eye and 20/200-1 with
pinhole in the left eye. On exam she continued to have
an afferent pupillary defect in the left eye and a pale
optic nerve. The patient had evidence of traction in the
retina temporally with neovascularization and vitreous
hemorrhage. She again underwent panretinal photocoagu-
lation to fill in areas in the far retinal periphery with the
aim to halt further ischemia-induced neovascularization.Patient #2
A 13-year-old African American female patient presented
to the emergency department in September 2011 with
fever, malar rash, and arthralgias. She was found to have
elevated lipase (491 Units/L; normal 10–180), amylase
(191 Units/L; normal 30–100), ESR (75 mm/hour; normal
0–20), CRP (1.15 mg/dL; normal <1.0), and CPK (344
Units/L; normal 30–170), Babesia titers, and Ehrlichiosis
titers. Rheumatology was consulted, and the patient was
found to be ANA positive, with antibodies to Smith,
dsDNA, RNP, and SS-A. Testing for anti-cardiolipin anti-
body, anti-β2 glycoprotein 1 antibody, and lupus anti-
coagulant was negative. Repeat Ehrlichiosis titers were
negative and her fever had resolved without specific anti-
microbial therapy. Repeat Babesia titers again revealed ele-
vated IgG and IgM levels. The patient was diagnosed with
SLE. Immunosuppression therapy was initially held until
Figure 2 Fluorescein angiography of Left eye of Patient #1 showing [a] large area of capillary non-perfusion (outlined by solid arrows)
and [b] superotemporal view showing distortion of vessels (asterisk) indicating traction, with area of non-perfusion.
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for possible Babesiosis.
Later that month, the patient complained of vision
changes in her right eye and was evaluated in the oph-
thalmology clinic, where her vision with correction was
20/80 in the right eye and 20/20 in the left eye. On di-
lated fundus examination a glistening sheen was noted
over the macula in the right eye, with intraretinal hemor-
rhages and cotton wool spots, without neovascularization.
It was concluded that she had retinal vasculitis associated
with SLE in the right eye. She was referred to a retinal spe-
cialist, who noted multiple cotton wool spots in the right
eye associated with two prominent branch retinal artery
occlusions along the superotemporal arcade. A single
cotton wool spot was visualized in the left posterior
pole (Figure 3). The patient was found to have anFigure 3 Photograph of right fundus of Patient #2 showing
scattered nerve fiber layer infarcts (solid arrows) and retinal
hemorrhage (outlined arrows).elevated ESR (79 mm/hour) and was hospitalized for
further management. The patient underwent MRI /MRA
brain, which showed no evidence of vasculitis. During
hospitalization, the patient received 3 doses of pulse
methylprednisolone (1,000 mg) as well as the first doses
of infusions of rituximab (750 mg/m2, 2 infusions given
2 weeks apart) and monthly cyclophosphamide
(750 mg/m2). She was also treated with a slow tapering
dose of oral prednisone.
On ophthalmologic follow-up in November 2011, the
patient’s vasculitic changes in her right macula were
judged to be 80% resolved (Figure 4). Her vision had im-
proved to 20/40 in the right eye, and her left eye vision
had remained stable at 20/20. She completed 7 total
monthly infusions of cyclophosphamide, followed by ini-
tiation of MMF 500 mg twice daily (300 mg/m2/dose;
dose not further increased due to lymphopenia) and
continued hydroxychloroquine 200 mg daily.
In April 2012, the patient returned to the retinal spe-
cialist. Her right eye vasculitis had almost completely re-
solved, with only subtle vascular changes visualized. Her
vision was 20/30 in the right eye and 20/20 in the left
eye with immunosuppressive therapy, not requiring laser
photocoagulation therapy or other ophthalmologic inter-
ventions. The patient remains stable and continues to be
treated with hydroxychloroquine and MMF.Conclusions
Among adults, retinopathy is reported to be a relatively
common manifestation of SLE. Retinal vasculitis may
precede the diagnosis of SLE, with visual loss being the
presenting symptom [8]. The findings often related to
SLE-associated retinopathy reflect vascular damage,
manifested by cotton wool spots, vascular hemorrhages,
and vasculitis. Some theories suggest that the underlying
Figure 4 Photographs of fundi of Patient #2 showing [a] Right fundus with improvement in changes caused by vasculitis and [b]
normal appearing fundus on the Left.
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vascular occlusion associated with circulating immune
complexes [9].
Retinal vasculitis is caused by an inflammatory process
and manifests as perivascular exudates and leakage of
dye along the veins, arteries, and capillaries on fluores-
cein angiography [3,10,11]. SLE retinal vasculitis often
manifests as an arteritis associated with microinfarction,
which then results in leakage of dye surrounding the
vessel walls [8].
A less common ophthalmic manifestation of SLE is oc-
clusive vascular disease, including retinal artery, arteri-
ole, or vein occlusion. The pathological process likely
involves immune complex deposition in retinal vessels,
leading to thrombosis [12]. Occlusion of the central ret-
inal artery manifests as sudden painless vision loss.
Without rapid restoration of circulation, the vision loss
is likely permanent due to infarction of the inner retina.
In a branch retinal artery occlusion, a permanent visual
field defect that corresponds to the infarcted vessel often
remains. Both occlusions often result in edema and
ischemia-driven neovascularization. Neovascularization
is accompanied by contractile tissue which may result in
a tractional retinal detachment. Separation of the vitre-
ous gel may tear the fragile new vessels, resulting in vit-
reous hemorrhage [9,13].
Furthermore, studies have demonstrated the correl-
ation between the presence of antiphospholipid anti-
bodies and retinopathy [8,13,14]. Anti-phospholipid
antibody syndrome (APS) is associated with arterial and
venous thrombosis, and Asherson, et al. described that
patients with SLE with elevated antiphospholipid anti-
body levels have an increased risk of developing vaso-
occlusive ocular disease [13]. Tests of anti-phospholipid
antibodies should likely be performed in all patients with
SLE as well as in patients that present with vaso-
occlusive retinopathy.
As the ocular manifestations of SLE are often associ-
ated with active systemic disease manifesting in other
organ systems, treating the systemic disease may result
in improvement of ocular disease. The mainstay oftreatment for SLE retinopathy is similar to the treatment
of SLE in general and involves the use of systemic gluco-
corticoids plus other immunosuppressant therapies
[15,16]. In the acute SLE-associated retinopathy setting,
patients are often treated with intravenous steroid pulse
therapy plus a cytotoxic agent, such as cyclophospha-
mide. Once disease control is attained, low-dose sys-
temic glucocorticoids and hydroxychloroquine are often
continued long-term to potentially prevent flares of
disease.
Local targeted therapies for SLE retinopathy may also
be of benefit. Pan-retinal photocoagulation (PRP) places
thermal burns via laser in the peripheral retina to de-
crease the metabolic demand of retinal tissue, inducing a
regression of neovascularization and is often employed
to control perivascular leakage associated with lupus ret-
inopathy. In addition, intravitreal anti-vascular endothelial
growth factor injections can be highly effective in reducing
macular edema and retinal neovascularization [17].
Multiple uncontrolled studies have demonstrated the
benefit and relative safety of rituximab, a chimeric
monoclonal antibody that depletes CD20+ B-cells, for
the treatment of severe or refractory SLE [18-21]. Unfor-
tunately, randomized controlled trials have not substan-
tiated this observed effectiveness of rituximab [22,23].
Uncontrolled studies have demonstrated the effective-
ness of rituximab specifically for the treatment of retinal
vasculitis, particularly in patients with Behcet’s disease
[24,25]. A recent case report described the rapid im-
provement in bilateral retinal vasculitis in a woman with
SLE following rituximab therapy [26].
The two pediatric patients described here had differ-
ent outcomes. In the second patient described, im-
munosuppression with pulse methylprednisolone in
addition to rituximab and cyclophosphamide infusions
were administered early in the disease course, while the
first patient received rituximab and cyclophosphamide
approximately one year after initial visual symptoms.
The second patient’s vision dramatically resolved, while
the first patient’s vision improved moderately from ini-
tial presentation but remained limited. While both
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branch retinal artery occlusions despite being negative
for antiphospholipid antibody syndrome, only the first
patient developed retinal neovascularization, warranting
PRP. In addition, this patient’s clinical course was com-
plicated by ischemic optic neuropathy.
The difference in the ophthalmic manifestations, dis-
ease progression, and outcomes of these two pediatric
patients with SLE highlights the spectrum of severity of
SLE retinopathy. Early recognition of retinal changes as
well as early rheumatologic and ophthalmologic inter-
vention may result in better outcomes. It is possible that
patient #2 had a superior visual outcome due to earlier
treatment with cyclophosphamide and rituximab. We
suggest that early intervention with B-cell depletion
therapy in addition to a traditional cytotoxic agent
should be considered in pediatric patients with SLE and
occlusive retinopathy.
This study reports two cases of pediatric patients with
SLE who presented with retinal vasculitis and occlusive
disease. Future studies are warranted to improve thera-
peutic measures for patients with SLE who present with
ocular disease.
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